After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on ...

Rakovina Therapeutics Inc. ('Rakovina” or the 'Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next ...

In spite of this underperformance, the clinical-stage TechBio firm continues to attract interest for its innovative approach ...

Roivant Sciences' 44% return highlights potential in its pipeline and partnerships. I maintain a cautious stance on RIOV ...

Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. Shares in biotech company Recursion ...

PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

Ultragenyx Pharmaceutical Inc. shares plunged 30% as UX143 trial raises efficacy doubts. Click for more on RARE and my ...

Merck announced plans to acquire Verona Pharma for roughly $10 billion. 1 As part of the agreement between the two companies, Merck will add Verona’s COPD treatment Ohtuvayre to its cardio-pulmonary ...

The funding will be deployed over a three-year period from 2025 to 2027, enabling Alfasigma to significantly advance its R&D ...